Coya Therapeutics stock reiterated at Buy by H.C. Wainwright on trial enrollment
H.C. Wainwright reiterated a Buy rating on Coya Therapeutics (COYA) with a $18.00 price target, citing full enrollment in its Phase 2/3 ALSTARS trial for ALS treatment. The stock trades at $4.85, suggesting over 270% upside. The trial aims to evaluate COYA 302's efficacy and safety, with top-line data expected in early Q2 2027. The company holds more cash than debt, providing financial flexibility.
How this was made
The 30-second read
Why it matters
The enrollment milestone reduces execution risk and supports the analyst's $18 price target, suggesting a near‑term upside opportunity.
Market read
The news provides fresh, material information for traders; the stock may rally on the enrollment update and analyst endorsement.
What to watch
Potential regulatory delays or manufacturing challenges for COYA 302 are not addressed.
Background
Coya Therapeutics (NASDAQ:COYA) is a clinical-stage biotech focused on low-dose IL‑2 and CTLA‑4 Ig therapies. The ALSTARS trial targets amyotrophic lateral sclerosis (ALS).
Ticker impact
Coya Therapeutics announced full enrollment of 120 participants in its Phase 2/3 ALSTARS trial for ALS, a new development first reported in this article.
likely upward pressure as the market prices in the successful enrollment milestone
Analyst reiterated a Buy rating with a $18 target, implying significant upside; enrollment news is material for a biotech.
Market effects
Positive signal for the ALS biotech niche and may lift peer companies developing similar immunotherapy approaches.
Limited to US biotech investors; no broader regional effect.
Minor global impact, confined to specialty biotech investors.
Counterpoint
If trial data later disappoints, the current optimism could reverse sharply.
Key entities
- CompanyCoya Therapeutics
Biotech developing COYA 302 for ALS.
- AnalystH.C. Wainwright
Equity research firm reiterating a Buy rating on COYA.
